AmeriCann Reports Q2 2022 Results
AmeriCann Reports Q2 2022 Results
Americann報告2022年第二季度業績
A summary of operational highlights included the following:
業務要點摘要包括以下內容：
- AmeriCann's Operating Revenue from Building 1 increased over 36% from the quarter ended June 30, 2021, to the quarter ending June 30, 2022. Net Income increased by $261,689 to $162,734.
- The Company achieved positive Adjusted EBITDA for the quarter of $438,890, an increase of 84% over the quarter ending June 2021. Adjusted Operating EBITDA margins for the quarter were 55.0%.
- The manufacturing of cannabis-infused products, including the 1906 branded "Drops," Howl's Tincture, and Harpoon Extracts, has increased dramatically at the Massachusetts Cannabis Center. Sales of manufactured infused products are expected to be even stronger as continual increases in production and sales for 1906 "Drops" are realized.
- The 1906 branded "Drops" has been the top-selling edible product in the Massachusetts market. Howl's Tincture was the top-selling brand in the tincture category.
- For the first five months of 2022, the total cannabis sales revenue for the Massachusetts market was $708 million, which was 16% greater than the first five months of 2021. The annualized revenue estimate based on the first five months of 2022 is approximately $1.7 billion. Experts believe the market will exceed $1.8 billion annually.
- The total Massachusetts market has sold $3.2 billion since the inception of the Commonwealth's regulated cannabis program.
- 從截至2021年6月30日的季度到截至2022年6月30日的季度，americann來自1號樓的運營收入增長了36%以上。淨收入增加261,689美元，達到162,734美元。
- 該公司在截至2021年6月的季度實現了438,890美元的調整後EBITDA正數，比上一季度增長了84%。該季度調整後的營業EBITDA利潤率為55.0%。
- 在馬薩諸塞州大麻中心，注入大麻的產品的製造，包括1906年品牌的“滴劑”、Howl‘s酊劑和魚叉提取物，都有了顯著的增長。隨着1906年“Drops”產品的生產和銷售實現持續增長，預計製造的輸液產品的銷售將更加強勁。
- 1906年品牌的“Drops”一直是馬薩諸塞州市場上最暢銷的食用產品。霍爾藥酒是該藥酒類別中最暢銷的品牌。
- 2022年前5個月，馬薩諸塞州市場的大麻銷售總收入為7.08億美元，比2021年前5個月增長了16%。基於2022年前五個月的年化收入估計約為17億美元。專家認為，這個市場每年將超過18億美元。
- 自英聯邦受管制的大麻計劃開始以來，馬薩諸塞州的市場總銷售額已達32億美元。